Personalized Medicine

Efficient and personalized patient management.

  • Rapid immunochromatography test
  • Qualitative detection of anti-infliximab antibodies in human whole blood, serum, or plasma
  • For in vitro diagnostic use

Easy to Use

Easy protocol with minimal steps.

  • 4 simple steps
  • 30 minutes to results
  • Fully decentralized, real point-of-care (POC)


Ready for the new emerging market players.

  • Detects anti-IFX antibodies in inflammatory bowel disease or rheumatic patients treated either with the reference infliximab (Remicade) or the biosimilars CT-P13 (Inflectra/Remsima) and SB2 (Flixabi/Renflexis)

Promonitor Quick

Promonitor Quick anti-IFX

This information is intended for physicians and healthcare professionals only.

Product registration and availability vary by country. For more information on product availability, please contact us here.